255 related articles for article (PubMed ID: 19713247)
1. Status of PI3K inhibition and biomarker development in cancer therapeutics.
Markman B; Atzori F; Pérez-García J; Tabernero J; Baselga J
Ann Oncol; 2010 Apr; 21(4):683-691. PubMed ID: 19713247
[TBL] [Abstract][Full Text] [Related]
2. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
Jiang BH; Liu LZ
Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
[TBL] [Abstract][Full Text] [Related]
3. Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.
Ogita S; Lorusso P
Target Oncol; 2011 Jun; 6(2):103-17. PubMed ID: 21547565
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt-mediated regulation of p53 in cancer.
Abraham AG; O'Neill E
Biochem Soc Trans; 2014 Aug; 42(4):798-803. PubMed ID: 25109960
[TBL] [Abstract][Full Text] [Related]
5. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
6. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
Haddadi N; Lin Y; Travis G; Simpson AM; Nassif NT; McGowan EM
Mol Cancer; 2018 Feb; 17(1):37. PubMed ID: 29455665
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
8. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.
Höland K; Salm F; Arcaro A
Curr Cancer Drug Targets; 2011 Oct; 11(8):894-918. PubMed ID: 21861842
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.
Dienstmann R; Rodon J; Markman B; Tabernero J
Recent Pat Anticancer Drug Discov; 2011 May; 6(2):210-36. PubMed ID: 21294710
[TBL] [Abstract][Full Text] [Related]
10. Targeting PI3K-AKT pathway for cancer therapy.
Lu Y; Wang H; Mills GB
Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
[TBL] [Abstract][Full Text] [Related]
11. Targeting phosphoinositide 3-kinase: moving towards therapy.
Marone R; Cmiljanovic V; Giese B; Wymann MP
Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
[TBL] [Abstract][Full Text] [Related]
12. PI3K-Akt pathway: its functions and alterations in human cancer.
Osaki M; Oshimura M; Ito H
Apoptosis; 2004 Nov; 9(6):667-76. PubMed ID: 15505410
[TBL] [Abstract][Full Text] [Related]
13. PI3K signalling: the path to discovery and understanding.
Vanhaesebroeck B; Stephens L; Hawkins P
Nat Rev Mol Cell Biol; 2012 Feb; 13(3):195-203. PubMed ID: 22358332
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
[TBL] [Abstract][Full Text] [Related]
15. PI3K pathway alterations in cancer: variations on a theme.
Yuan TL; Cantley LC
Oncogene; 2008 Sep; 27(41):5497-510. PubMed ID: 18794884
[TBL] [Abstract][Full Text] [Related]
16. New phosphatidylinositol 3-kinase inhibitors for cancer.
Bowles DW; Jimeno A
Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
[TBL] [Abstract][Full Text] [Related]
17. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
Klempner SJ; Myers AP; Cantley LC
Cancer Discov; 2013 Dec; 3(12):1345-54. PubMed ID: 24265156
[TBL] [Abstract][Full Text] [Related]
18. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
[TBL] [Abstract][Full Text] [Related]
19. PI3K pathway inhibitors: better not left alone.
Markman B; Tao JJ; Scaltriti M
Curr Pharm Des; 2013; 19(5):895-906. PubMed ID: 22973958
[TBL] [Abstract][Full Text] [Related]
20. Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
West KA; Castillo SS; Dennis PA
Drug Resist Updat; 2002 Dec; 5(6):234-48. PubMed ID: 12531180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
